Missed Opportunities: Tools, Tips, and Techniques to Improve the Detection of Bipolar I DisorderPremiere Date: Wednesday, November 18, 2020
This activity offers CE credit for:%>
- Physicians (CME)
- Pharmacists (ACPE)
- ABIM (MOC)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Thursday, November 18, 2021
Note: Credit Is No Longer Available
|Roger S. McIntyre, MD, FRCPC
University of Toronto
University Health Network
Chairman and Executive Director, Brain and Cognition, Depression and Bipolar Support Alliance (DBSA)
Clinical Professor, Department of Psychiatry and Neurosciences
University of California School of Medicine
There are many factors impeding the accurate diagnosis of bipolar disorder, including that it is difficult to differentiate bipolar I disorder (BD-I) and bipolar II disorder (BD-II) from unipolar depression, particularly in those with no clear history of mania or hypomania or who present during a depressive episode. Additionally, the prevalence of depressive symptoms is higher than that of hypomanic or manic symptoms during the course of BD-I or BD-II, with the proportion of time ill accounted for by depression being 70% in BD-I and 80% in BD-II. Therefore, it is imperative that physicians note diagnostic criteria and diagnostic aids and utilize rapid assessment tools such as the Mood Disorders Questionnaire (MDQ), Composite International Diagnostic Interview (CIDI), and the Rapid Mood Screener (RMS) when assessing mood disorders.
In this CME Outfitters BriefCase, expert faculty will present a patient case that shows how to detect BD-I, differentiate BD-I and BD-II and other mimickers, and use evidence-based screening tools to improve detection of BD-I in order to promote early administration of effective care.
At the end of this CE activity, participants should be able to:
- Implement diagnostic criteria and evidence-based tools to improve detection of bipolar I disorder for early administration of effective care.
The following learning objectives pertain only to those requesting CNE or CPE credit:
- Assess diagnostic criteria and evidence-based tools to improve the detection of bipolar I disorder for early administration of effective care.
Supported by an educational grant from Otsuka America Pharmaceutical, Inc. and Lundbeck
Psychiatrists, primary care physicians, PAs, nurse practitioners, nurses, and pharmacists
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Outfitters, LLC, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 0.5 contact hours (0.05 CEUs) Universal Activity Number:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
ABPN MOC: ABPN Diplomates may select any CME activity relevant to their practice to count towards ABPN MOC requirements.
Royal College MOC: Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered
MIPS Improvement Activity: This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Note to PAs: PAs may claim a maximum of .5 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.
Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. McIntyre reports that he receives grants/research support from The Canadian Institutes of Health Research (CIHR); Global Alliance for Chronic Diseases (GACD); National Natural Research Foundation of China; and Stanley Medical Research Institute. He is a consultant/on the speakers bureau for Allergan; Intra-Cellular Therapies Inc.; Janssen Pharmaceutical, Inc.; Lundbeck Canada Inc.; Minerva Neurosciences; Neurocrine Biosciences, Inc.; Otsuka Canada Pharmaceutical Inc.; Pfizer Inc.; Purdue Pharma Canada; Sunovion Pharmaceuticals Canada Inc.; and Takeda Pharmaceutical Company Limited.
Tony Graham, MD (peer reviewer) has no disclosures to report.
Mae Ochoa, RPh (peer reviewer) has no disclosures to report.
Kashemi D. Rorie, PhD (planning committee) has no disclosures to report.
Evan Luberger (planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).